ALI HEALTH (00241) saw its shares rise nearly 4%. As of the time of writing, the stock was up 3.29%, trading at HKD 5.96, with a turnover of HKD 519 million. On the news front, according to an announcement on ALI HEALTH's official WeChat account, on January 8, the company entered into a strategic partnership with Beijing Meiersen Pharmaceutical Technology Development Co., Ltd., jointly announcing an in-depth collaboration in the field of innovative specialized pediatric drugs. The collaboration will focus on Beimeijing® (Timolol Maleate Gel), the world's first approved topical innovative drug for treating proliferative superficial infantile hemangiomas, encompassing deep coordination from patient education and charitable assistance to a full-channel exclusive launch. Historically, there has been a lack of topical hemangioma treatment drugs specifically designed for infants and young children in the domestic market. Beimeijing® is not only the world's first topical gel formulation for this specific indication but also represents a significant breakthrough in China, spanning from scientific research innovation to industrial transformation in the development of specialized pediatric improved new drugs. Beimeijing® (Timolol Maleate Gel) is scheduled for an exclusive online launch across ALI HEALTH's platforms on January 13.
Comments